ProCE Banner Activity

New Immunotherapy Options in Acute Lymphoblastic Leukemia: Implications for Nurses—Downloadable Webcast

Multimedia
In this on-demand Webcast, Sara Tinsley, PhD, ARNP, AOCN, reviews nursing strategies and key data on the latest immunotherapies for ALL.

Released: March 01, 2019

Expiration: February 29, 2020

Share

Faculty

Sara Tinsley-Vance

Sara Tinsley-Vance, PhD, MSN, APRN-BC, AOCN

Nurse Practitioner and Researcher
Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Pfizer, Inc.

Target Audience

This program is intended for oncology nurses and other healthcare providers who care for patients with acute lymphoblastic leukemia.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Explain to patients with ALL the limitations of standard treatment and potential benefit for novel immunotherapy options
  • Discuss the relative merits of single-agent immunotherapies vs antibody–drug conjugates vs CAR T-cell therapy for the treatment of ALL
  • Query patients for their preferences which may have a direct impact on choice of treatment for their ALL
  • Apply preventive as well as management strategies for treatment-related toxicities associated with novel therapeutics in ALL, including veno-occlusive disease and cytokine-release syndrome
  • Communicate effectively with patients to involve them in the prevention and management of treatment-related toxicities associated with novel therapeutics in ALL

Disclosure

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Sara Tinsley-Vance, PhD, MSN, APRN-BC, AOCN

Nurse Practitioner and Researcher
Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Sara Tinsley, PhD, ARNP, AOCN, has no real or apparent conflicts of interest to report.

Staff Disclosure

Staff

Krista Marcello,

Associate Managing Editor

Krista Marcello has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin L. Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Joint Accreditation Statement
In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosure of Unlabeled Use

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

The PIM planners and managers have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 01, 2019, through February 29, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve oncology nurses’ ability to educate, partner in shared decision making with, and optimally care for patients with acute lymphoblastic leukemia.